Latest: FDA Approves New Biosimilar for Oncology Treatment

Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

0 Mins
Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago